The Bio-Rad MONOLISA Anti-HBs EIA is for In Vitro Diagnostic Use and it has the catalog number 25220. It is a qualitative and quantitative enzyme immunoassay for the detection of antibody for hepatitis B surface antigen in human serum and EDTA or citrated plasma. The Bio-Rad MONOLISA Anti-HBs EIA is a qualitative and quantitative enzyme immunoassay for the detection of antibody for hepatitis B surface antigen in human serum and EDTA or citrated plasma. The assay results may be used as an aid in the determination of susceptibility to hepatitis B virus (HBV) infection in individuals prior to or following HBV vaccination or where vaccination status is unknown. Assay results may be used with other HBV serological markers for the laboratory diagnosis of HBV disease associated with HBV infection.
Publicado el 26 de septiembre de 2012 · Inicio del retiro: 27 de julio de 2012
Resumen
FDA registra el retiro Z-2398-2012 de dispositivos médicos de Clase II, publicado el 26 de septiembre de 2012 e iniciado el 27 de julio de 2012. Empresa responsable: Bio-Rad Laboratories; Estado: Finalizado; Cantidad reportada: 7,400 (approximately)- All lots since distribution date May 9, 2007; Lote: All lots distributed from May 5, 2007. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Prolonged exposure of the MONOLISA Anti-HBs EIA Conjugate Diluent component to light may result in elevated Optical Densities (OD) in some samples such that a negative sample could elevate to a grey zone or low positive result.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Bio-Rad Laboratories
- Distribuidor
- Worldwide distribution: USA (nationwide) and countries of: Canada, South Africa, and Zimbabwe.
- Lote
- All lots distributed from May 5, 2007
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDABio-Rad, REF: 12005660, QXDx BCR-ABL %IS Kit3 de abril de 2024
- FDAFSE Image Upgrade Kit, Catalog # 92019C This kit is used to install and/or upgrade software used with the30 de octubre de 2013
- FDABD FACS 7-color Setup beads BD Biosciences, San Jose, CA 95131. BD FACS 7 color Setup Beads are for in vitro26 de septiembre de 2012
- FDAJUGGERKNOT IN®GUIDE PUNCH, 2.9MM. The JuggerKnot 2.9mm In-Guide Punch is intended to be used to prepare a26 de septiembre de 2012
- FDAInfinity® sampling device, Cytology Brush, United States Endoscopy Group, Inc., 5976 Heisley Road, Mentor, OH26 de septiembre de 2012
- FDAGuardian II Hemostasis Valve, Model 8210 and Guardian II NC Hemostasis Valve, Model FH102. Intended to26 de septiembre de 2012
Preguntas sobre este retiro
¿The Bio-Rad MONOLISA Anti-HBs EIA is for In Vitro Diagnostic Use and it has the catalog number 25220. It is a qualitative and quantitative enzyme immunoassay for the detection of antibody for hepatitis B surface antigen in human serum and EDTA or citrated plasma. The Bio-Rad MONOLISA Anti-HBs EIA is a qualitative and quantitative enzyme immunoassay for the detection of antibody for hepatitis B surface antigen in human serum and EDTA or citrated plasma. The assay results may be used as an aid in the determination of susceptibility to hepatitis B virus (HBV) infection in individuals prior to or following HBV vaccination or where vaccination status is unknown. Assay results may be used with other HBV serological markers for the laboratory diagnosis of HBV disease associated with HBV infection. fue retirado del mercado?
Sí. FDA publicó el retiro Z-2398-2012 el 26 de septiembre de 2012. Peligro reportado: Prolonged exposure of the MONOLISA Anti-HBs EIA Conjugate Diluent component to light may result in elevated Optical Densities (OD) in some samples such that a negative sample could elevate to a grey zone or low positive result.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter